Sunday, March 19, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

DARPA Funding for Innovative ‘Blood Cleaning’ Device

by Global Biodefense Staff
May 16, 2012

Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals to integrate the component technologies developed in the Dialysis Like Therapeutics (DLT) program. The goal of DLT is to develop a portable device that removes “dirty” blood from the body, separates harmful agents, and returns “clean” blood to the body in a manner similar to dialysis treatment of kidney failure. The envisioned device will manipulate key health parameters faster than the underlying disease process and drive the patient towards a stable, healthy state.

While development of such a device would have impact across a wide range of biothreats, the initial target application is sepsis.  Combat wound infection and the overwhelming blood infection called sepsis are significant problems for U.S. military personnel. When sepsis is complicated by shock, approximately half of these patients do not survive for 30 days, even if effective antibiotics are used. The fatality rate from sepsis can be high, given that antibiotic-resistant bacteria are an increasing problem for injured warfighters and military treatment facilities.

Current culture-based methods of identifying blood-borne pathogens may take 48 hours or longer to identify the offending pathogen, and some blood-borne pathogens do not propagate in culture. Pending these culture results, septic patients are treated with protocol-based broad spectrum antibiotics. In the event the offending pathogen is resistant to the empirically chosen antibiotic, the fatality rate may increase as much as 9% per hour.

As a first step towards reducing the impact of sepsis, DARPA selected teams of performers proposing against a prior BAA (DARPA-BAA-11-30) to develop dialysis-like therapeutic technologies to treat sepsis by sensing and removing sepsis-related targets such as blood-borne pathogens or inflammatory cytokines. The focus of this solicitation (DARPA-BAA-12-36) is to integrate key component technologies (sensing, complex fluid manipulation architectures, separation technologies, and closed-loop controller) that are being developed under DARPA-BAA-11-30 into a functioning device that can effectively treat sepsis across the military health system.

Final program metrics require a device capable of removing at least 90% of unknown pathogens, cytokines, toxins, and activated cells from a patient in one day. In vivo experiments in a clinically relevant animal model will validate the device for use in sepsis.  At the completion of the program the device will be expected to have adequate testing (bench and animal) completed and a clinical protocol prepared in order to gain Investigational Device Exemption (IDE) approval from the Food and Drug Administration (FDA).

Multiple awards under this BAA are expected to be issued in October, 2012. Full details are available under Solicitation Number: DARPA-BAA-12-36. The proposal response deadline is July 13, 2012.

Tags: Animal ModelsAntimicrobialsBAADARPAPOC DiagnosticsRFISepsis

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC